[Comparative study of the therapeutic effect of the glycopeptide antibiotics eremomycin, vancomycin and ristomycin in a model of antibiotic-associated colitis in golden hamsters].
Experiments with a model of intraperitoneal or intragastric lincomycin-induced fatal colitis indicated that eremomycin, vancomycin and ristomycin administered orally in daily doses of 100, 100 and 200 mg/kg, respectively, for 5 days protected the animals from development of antibiotic-associated colitis (AAC), which was evident from prolongation of their life-span to 10-23 days against 3-9 days in the controls. Eremomycin administered intraperitoneally according to an analogous scheme protected the animals from development of AAC, prevented 45 per cent of the animals from death and prolonged the life-span of the other animals to 15-28 days against 3-9 days in the controls. Vancomycin administered intraperitoneally was somewhat more efficient. Still, unlike eremomycin it had a local irritating effect. The protective effect of ristomycin administered intraperitoneally was much lower than that of vancomycin and eremomycin.
Rukhlina
A A
AA
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy*; D006224:Cricetinae; D004195:Disease Models, Animal; D005260:Female; D006020:Glycopeptides; D007274:Injections, Intraperitoneal; D008034:Lincomycin; D008647:Mesocricetus; D012310:Ristocetin / Q000008:administration & dosage / Q000627:therapeutic use*; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D006020:Glycopeptides; C053759:eremomycin; D012310:Ristocetin; D014640:Vancomycin; D008034:Lincomycin
Sravnitel'noe izuchenie lechebnogo deĭstviia glikopeptidnykh antibiotikov éremomitsina, vankomitsina i ristomitsina na modeli antibiotikoassotsiirovannogo kolita zolotistykh khomiakov.